↓ Skip to main content

Loxapine for schizophrenia

Overview of attention for article published in Cochrane database of systematic reviews, October 2007
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
8 tweeters
weibo
1 weibo user
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
102 Mendeley
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Loxapine for schizophrenia
Published in
Cochrane database of systematic reviews, October 2007
DOI 10.1002/14651858.cd001943.pub2
Pubmed ID
Authors

Abhijit Chakrabarti, Anne-Marie Bagnall, Pierre Chue, Mark Fenton, Vikram Palanisamy, Winson Wong, Jun Xia

Abstract

Some authors have suggested that loxapine is more effective than typical antipsychotics in reducing the negative symptoms of schizophrenia, that extrapyramidal adverse effects are not usually seen at clinically effective antipsychotic doses and that it should therefore be classed as atypical. To determine the effects of loxapine compared with placebo, typical and other atypical antipsychotic drugs for schizophrenia and related psychoses. For this 2007 update, we searched the Cochrane Schizophrenia Group's Register (January 2007). We included all randomised controlled clinical trials relevant to the care of schizophrenia that compared loxapine to other treatments. We independently inspected abstracts ordered papers, re-inspected and quality assessed these. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a fixed effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. For continuous data, we calculated weighted mean differences (WMD) again based on a fixed effects model. We were able to include 41 studies in this review. Compared with placebo, loxapine has an antipsychotic effect (Global effect - not improved at six weeks: n=78, 2 RCTs, RR 0.30 CI 0.1 to 0.6 NNT 3 CI 3 to 5). It is as effective as typical drugs in the short term (4 -12 weeks) (Global effect: n=580, 13 RCTs, RR 0.86 CI 0.7 to 1.1; mental state: n=915, 6 RCTs, RR 0.89 CI 0.8 to 1.1). Very limited heterogeneous data suggest that, given intramuscularly (IM), loxapine may be at least as sedating as IM haloperidol and thiothixene. Loxapine is also as effective as atypicals (risperidone, quetiapine) (n=468, 6 RCTs, RR mental state not improved 1.07 CI 0.8 to 1.5). Adverse effect profile is similar to typicals but loxapine may cause more extrapyramidal adverse effects when compared with atypicals (n=340, 4 RCTs, RR 2.18 CI 1.6 to 3.1). Loxapine is an antipsychotic which is not clearly distinct from typical or atypical drugs in terms of its effects on global or mental state. Loxapines profile of adverse effects is similar to that of the older generation of antipsychotic drugs.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Chile 1 <1%
South Africa 1 <1%
United Kingdom 1 <1%
Canada 1 <1%
Unknown 97 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 19 19%
Researcher 17 17%
Student > Ph. D. Student 11 11%
Student > Bachelor 10 10%
Student > Doctoral Student 8 8%
Other 26 25%
Unknown 11 11%
Readers by discipline Count As %
Medicine and Dentistry 43 42%
Psychology 17 17%
Nursing and Health Professions 8 8%
Pharmacology, Toxicology and Pharmaceutical Science 7 7%
Social Sciences 3 3%
Other 10 10%
Unknown 14 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 February 2017.
All research outputs
#2,262,803
of 13,755,408 outputs
Outputs from Cochrane database of systematic reviews
#5,059
of 10,735 outputs
Outputs of similar age
#31,524
of 188,262 outputs
Outputs of similar age from Cochrane database of systematic reviews
#105
of 206 outputs
Altmetric has tracked 13,755,408 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,735 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,262 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 206 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.